Sonoma Pharmaceuticals updates investor presentation; no material changes

Sonoma Pharmaceuticals, Inc.

HOCl product portfolio covers wound, eye, oral, nasal, dermatology, podiatry, and animal health
Products sold in 55 countries via direct sales and distribution partners
No new financial guidance or material business developments in the presentation

item 7.01 item 9.01

Sonoma Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-002051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.